| Literature DB >> 27041639 |
A Alcántara Montero1, C I Sánchez Carnerero2.
Abstract
Many women will likely experience a sexual problem in their lifetime. Female sexual dysfunction is a broad term used to describe 3 categories of disorders of a multifactorial nature. Effective, but limited pharmacotherapeutic options exist to address female sexual dysfunction. The FDA recently approved the first agent for treatment of hypoactive sexual desire disorder in pre-menopausal women. Off-label use of hormonal therapies, particularly oestrogen and testosterone, are the most widely employed for female sexual dysfunction, particularly in post-menopausal women. Other drugs currently under investigation include phosphodiesterase inhibitors and agents that modulate dopamine or melanocortin receptors.Entities:
Keywords: Disfunción sexual en mujeres; Flibanserin; Flibanserina; Hypoactive sexual desire disorder; Sexual dysfunction in women; Trastorno del deseo sexual hipoactivo
Mesh:
Substances:
Year: 2016 PMID: 27041639 DOI: 10.1016/j.semerg.2016.02.008
Source DB: PubMed Journal: Semergen ISSN: 1138-3593